SENORES PHARMACEUTICALS L (SENORES) Fair Value & Analysis
Healthcare · IN · Market cap ₹63.6B
Fair value as of: Aug 13, 2026
From 14 valuation models · updated 4 days ago
Share price +10.0% over the past month.
Below-average quality, and screening another 76% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹482.88). The favourable scenario is already priced in.
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (20 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
20‑month range ₹444.30 – ₹1,546 · fair‑value band ₹271.47 – ₹482.88 · the ₹1,546 price screens above the ₹375.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
SENORES PHARMACEUTICALS L (SENORES) currently trades at ₹1,546, while our model-based Fair Value estimate is ₹375.36, implying the stock looks roughly 75.7% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, SENORES PHARMACEUTICALS L generated revenue of ₹6.3B at a net margin of 18.4%. Revenue grew 53.4% year over year. It earns a return on equity of 13.8%. Net debt stands at ₹3.0B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹271.47 (bear case) to ₹482.88 (bull case); at ₹1,546, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 177% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at -76%, SENORES screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Growth Earnings (₹1,164) versus Asset-Based (₹135.82). Highest evidence: ROIC Compounder (72).
Notify me when SENORES reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 84
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally.
Full company description
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
SENORES PHARMACEUTICALS L reported revenue of ₹6.3B in FY2026 versus ₹141M in FY2022, a compound +159.0%/yr. Reported net income was ₹1.2B in FY2026, compounding +228.5%/yr from FY2022.
SENORES screens 76% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 77 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,220 | $389.47 | -68% |
| Johnson & Johnson, JNJ | $260.86 | $169.04 | -35% |
| AbbVie Inc ABBV | $248.76 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €240.14 | -39% |
| Merck & Co MRK | €115.42 | €118.21 | +2% |
| Novartis AG NVSN | 2,742 MXN | 1,964 MXN | -28% |
| AstraZeneca PLC AZN | $158.50 | $127.32 | -20% |
| Novo Nordisk A/S NOVOB | kr 299.50 | kr 409.46 | +37% |
| Sanofi SNYN | 770.00 MXN | 1,041 MXN | +35% |
| GSK plc GSKN | 917.00 MXN | 879.08 MXN | -4% |
Compare SENORES PHARMACEUTICALS L with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SENORES PHARMACEUTICALS L (SENORES) overvalued or undervalued?
What is the fair value of SENORES?
What is the quality score of SENORES?
What is the revenue of SENORES PHARMACEUTICALS L (SENORES)?
What is the net profit margin of SENORES?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SENORES PHARMACEUTICALS L and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.